Protein phosphatase methylesterase-1 (PME-1) expression predicts a favorable clinical outcome in colorectal cancer

Amanpreet Kaur1,2,3,*, Adam Elzagheid1,4,5,*, Eva-Maria Birkman1, Tuulia Avoranta1,6,7, Ville Kytölä8, Eija Korkeila6, Kari Syrjänen9,10, Jukka Westermarck1,2 & Jari Sundström1

1Department of Pathology, University of Turku, Turku 20520, Finland
2Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku 20520, Finland
3TuBS and TuDMM Doctoral Programmes, Turku 20520, Finland
4Department of Pathology, Faculty of Medicine, Benghazi University PO Box 1308 Benghazi, Libya
5Biotechnology Research Center, Tripoli, Libya
6Department of Oncology and Radiotherapy, University of Turku and Turku University Hospital, Turku 20521, Finland
7Department of Social Services and Healthcare, City of Helsinki, Helsinki 00099, Finland
8BioMediTech, University of Tampere, Tampere 33520, Finland
9Department of Clinical Research, Biohit Oyj, Helsinki 00880, Finland
10Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil

Keywords
Biomarker, colorectal cancer, PME-1, PP2A, survival, TCGA

Abstract
Colorectal cancer (CRC) accounts for high mortality. So far, there is lack of markers capable of predicting which patients are at risk of aggressive course of the disease. Protein phosphatase-2A (PP2A) inhibitor proteins have recently gained interest as markers of more aggressive disease in certain cancers. Here, we report the role of PP2A inhibitor PME-1 in CRC. PME-1 expression was assessed from a rectal cancer patient cohort by immunohistochemistry, and correlations were performed for various clinicopathological variables and patient survival. Rectal cancer patients with higher cytoplasmic PME-1 protein expression (above median) had less recurrences ($P = 0.003, n = 195$) and better disease-free survival (DFS) than the patients with low cytoplasmic PME-1 protein expression (below median). Analysis of $PPME1$ mRNA expression from TCGA dataset of colon and rectal adenocarcinoma (COADREAD) patient cohort confirmed high $PPME1$ expression as an independent protective factor predicting favorable overall survival (OS) ($P = 0.005, n = 396$) compared to patients with low $PPME1$ expression. CRC cell lines were used to study the effect of PME-1 knockdown by siRNA on cell survival. Contrary to other cancer types, PME-1 inhibition in CRC cell lines did not reduce the viability of cells or the expression of active phosphorylated AKT and ERK proteins. In conclusion, PME-1 expression predicts for a favorable outcome of CRC patients. The unexpected role of PME-1 in CRC in contrast with the oncogenic role of PP2A inhibitor proteins in other malignancies warrants further studies of cancer-specific function for each of these proteins.

Introduction
Colorectal cancer (CRC) is the third most common malignant neoplasm in many countries of the western world [1]. Its prognosis has improved gradually as a result of advancements in surgery and adjuvant chemotherapy [2]. However, a significant proportion of the patients still die of the disease [3]. There is a need for biomarkers to predict which patients are at risk of disease recurrence. This would help to direct adjuvant treatments to those patients that gain benefit from them and protect the low-risk patients from the side effects of therapy.

Protein phosphatase-2A (PP2A) is a human tumor suppressor, which protects against cellular transformation. It is the major serine–threonine phosphatase, which functions by negatively regulating the activity of numerous signaling...
proteins important for malignant neoplasms [4–6]. Consequently, the neoplasms have developed various mechanisms to oppose the PP2A activity [5, 7]. Among these, three important endogenous PP2A inhibitors have been found: CIP2A, SET, and PME-1 [5, 7–9]. Overexpression of CIP2A on protein level has been found in many human neoplasms, and it is a marker of poor outcome in several malignant neoplasms including CRC [10, 11]. SET in turn seems to be particularly important in hematological malignancies [12]. PME-1 expression has been studied in only a limited number of human neoplasms, such as astrocytic gliomas, and endometrial, lung, and gastric cancers [9, 13, 14]. Elevated amounts of PME-1 have been found in endometrial and glial tumors, which are linked to the altered ERK pathway signaling, cell proliferation, and disease progression of gliomas to malignant subtypes [9, 13]. Additionally, a small fraction (3–4%) of the gastric and lung cancer patients shows PPME1 gene amplification, which also corresponds to elevated PME-1 protein expression and activation of ERK and AKT survival signaling [14]. These studies have highlighted potential oncogenic role of PME-1 in these malignant neoplasms. However, whether oncogenic function of PME-1 can be generalized to various human cancer types is as yet unclear. Also, the studies so far have failed to identify any correlation between tumor PME-1 expression and the patient survival.

In this study, we report the immunohistochemical analysis of PME-1 protein expression in the tumor material of a rectal cancer patient cohort, and its correlation to the clinicopathological parameters as well as patient survival. Unexpectedly, in strike contrast with its previously shown oncogenic role in other malignancies, we show that high PME-1 expression correlates with superior clinical outcome in CRC. The association of high PME-1 expression with better patient survival is confirmed at the mRNA level by using an independent CRC dataset. Finally, consistent with unexpected role for PME-1 in CRC, PME-1 inhibition in two human colon cancer cell lines fails to show any inhibitory effect on either cell survival or expression of phosphorylated AKT or ERK, shown to be regulated by PME-1 in other previously studied cancer types.

Materials and Methods

Cell culture and siRNA transfections

Human colon carcinoma cell lines HCA-7 and CW-2 (gifted by Prof. Olli Carpén, University of Turku) were cultured in DMEM (Sigma-Aldrich, Finland Oy, Helsinki, Finland) and RPMI (Sigma-Aldrich) media, respectively, supplemented with 10% heat-inactivated FBS (Gibco, Life Technologies, Carlsbad, CA, USA). Cells were transfected with siRNA (Eurofins MWG Synthesis GmbH, Germany). Three days after transfections, cells were harvested for analysis.

Western blotting

Cells were lysed in 2× SDS sample buffer/Laemmli Buffer, boiled, and resolved by SDS-PAGE. Proteins were transferred to PVDF membranes (Millipore, Merck KGaA, Darmstadt, Germany), which were blocked and incubated with required dilution of primary (at +4°C, incubated overnight) and 1:5000 dilution of secondary antibody (at room temperature, for 1 h) in 5% milk-TBS-Tween-20, and developed by enhanced chemiluminescence (Pierce Biotecology, Rockford, IL, USA). Loading control antibody for GAPDH (5G4-6C5) (1:200,000 dilution) was from Santa Cruz Biotechnology Inc., Dallas, TX, USA. Antibody for phosphorylated AKT-1/2/3 (Thr308) (sc-16646) antibody used at 1:500 dilution were purchased from Santa Cruz Biotechnology Inc., Dallas, TX, USA. Antibody for phosphorylated ERK-1/2 (Thr202/Tyr204) (#4370) used at 1:1000 dilution was purchased from Cell Signalling Technology, Danvers, MA, USA. Loading control antibody for GAPDH (5G4-6C5) (1:200,000 dilution) was from HyTest Ltd., Turku, Finland. Densitometric analysis of the blots was performed using Image Lab software (Bio-Rad Laboratories Inc., Hercules, CA, USA).

Immunofluorescence

Cells were seeded on glass coverslips and transfected with siRNA. After 3 days, cells were fixed with 4% paraformaldehyde (Sigma-Aldrich) and permeabilized with 0.5% Triton X-100 (Sigma-Aldrich) at room temperature for 10 and 5 min, respectively. Immunostainings were carried out with anti-PME-1 antibody (clone B-12, sc-25278) at 1:50 dilution in 10% goat serum blocking buffer, overnight at +4°C under constant rocking. Negative control coverslips were incubated with blocking buffer alone (without PME-1 antibody). After 2–3 washes with PBS, coverslips were incubated with Alexa-594-conjugated goat anti-mouse secondary antibody (A-11005; Invitrogen, Life Technologies, Carlsbad, CA, USA), 2 mmol/L l-glutamine, and penicillin (50 units/mL)–streptomycin (50 μg/mL) in a humidified atmosphere of 5% CO2 at 37°C.

Small interfering RNA (siRNA) transfections were performed with Lipofectamine RNAiMAX reagent (Invitrogen, Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions with the final siRNA concentration of 50 nmol/L per well. The scrambled (Scr) or control (5′-GUA ACA AUG AGA GCA CGG C-3′) and PME-1-specific (5′-GGA AGU GAG UCU AUA AGC A-3′) siRNAs were purchased from Eurofins MWG Synthesis GmbH, Germany. Three days after transfections, cells were harvested for analysis.
Cell viability assays

Cell viability was determined by two different assays; CellTiter-glo (CTG) (Promega Corp., Madison, WI, USA) and cell proliferation reagent WST-1 (Roche Diagnostics GmbH, Mannheim, Germany). CTG assay measures the cellular ATP levels as an indicator of metabolically active and viable cells. WST-1 assay is dependent on NAD(P)H production by glycolysis and the activity of mitochondrial dehydrogenase enzymes, an indicator of metabolically active viable cells. Both the assays were performed as per the manufacturer’s recommendations. CTG assay was performed in polystyrene 96-well plates (Nunc, Thermo Fisher Scientific Inc., Paisley, UK) and luminescence was measured with Synergy H1 hybrid plate-reader (BioTek, Winooski, VT, USA). The WST-1 assay was performed in clear bottom 96-well plates and the absorbance was measured at 450 nm.

Tumor samples

Formalin-fixed, paraffin-embedded tumor samples were collected from patients treated for rectal cancer at Turku University Central Hospital between 2000 and 2009. These included operative samples (n = 210) with tumors of the middle and lower rectum from the archives of the Department of Pathology, Turku University Hospital. Superficial tumors operated by local excision were excluded from the study as well as patients with distant metastases at the time of diagnosis. The permission for using the archival tissue material was granted by the National Supervisory Authority for Welfare and Health, Finland (permission # Dnro 1709/32/300/02, 13 May 2002).

For tumor staging, we applied the sixth edition of TNM classification of malignant tumors in use at the time the patients were operated [16]. Treatment was chosen according to preoperative tumor staging, including computed tomography (CT) or magnetic resonance imaging (MRI) of the rectum, CT of the abdomen, and X-ray or CT of the chest. Patients were treated either with short-course preoperative radiotherapy (RT) (n = 88), long-course preoperative (chemo) RT (n = 52), or received no treatment before surgery (n = 70) on the basis of common clinical recommendations [17]. Short-course RT was given 5 Gy fractions on 5 days, and the patients were operated on the following week. Long-course RT was delivered in 1.8 Gy fractions to a total dose of 50.4 Gy in 6 weeks with (n = 43) or without (n = 9) chemotherapy. At that period, patients were operated 5–7 weeks after RT. The cytostatic treatment included either bolus 5-fluorouracil (n = 4) or capecitabine (n = 39). The type of surgery was anterior resection among 113 (54%), and abdomino-perineal resection among 93 (44%) patients. Four (2%) patients were operated with low Hartmann’s procedure or other type of surgery. The majority of the specimens (n = 154) were screened to detect vascular invasion, which was found in 44 (28.6%) samples. Patients with established high-risk features were treated with adjuvant chemotherapy. The median follow-up time was 62.5 months. Disease recurrence was observed among 65 (31%) patients, either local or distant one. The clinical information of the patients is shown in Table 1.

Immunohistochemistry

Four of the 210 patients had no viable cancer cells left after preoperative treatment, classified as pT0. The amount of cancer cells was too scarce for a reliable evaluation of immunohistochemical staining in additional 11 patients. Consequently, samples of 195 patients were included in the final analysis. The most optimal paraffin blocks were selected to get enough tumor material for analyses. Sections of 5 μm were cut. The antigen retrieval was performed with microwave oven twice for 7 min in 10 mmol/L sodium citrate buffer, pH 9. For immunohistochemical staining, monoclonal mouse-anti-human PME-1 (clone B12) antibody epitope corresponding to amino acids 161–386 of PME-1 of human origin (Santa Cruz Biotechnology, sc-25278), at a dilution of 1:200 was used. For detection, the EnVisionTM + Dual Link System- HRP (Dako, Glostrup, Denmark) was utilized.

Analysis of PME-1 expression

Two observers blinded to the clinical data evaluated the cytoplasmic and nuclear IHC staining of PME-1 (A.E. all samples and E.M.B. 40 samples). Tissue from human glioblastoma was used as positive control. Both nuclear and cytoplasmic staining was scored on a scale of four intensity levels (+++, ++, +, −). The strong staining intensity (++++) corresponds to the positive control of PME-1; weak staining intensity can still be distinguished from the background. Moderate staining intensity is intermediate between the previous ones. After estimating the predominant cytoplasmic and nuclear staining in each sample, the intensity was scored for each staining site (nucleus, cytoplasm) as follows: 0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining, and 4 = positive staining. The intensity grade was calculated as the sum of the scores of both staining sites. The intensity grade was assigned to each sample as follows: 0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining, and 4 = positive staining. Then, the median intensity grade was calculated for each group of patients and compared using the Mann-Whitney U test. A p-value less than 0.05 was considered statistically significant.
intensities, staining indices were analyzed. These include the most intensive cytoplasmic and nuclear indices. To calculate these indices, the area of the most intensive staining in cancer cells was chosen from each sample. After that, the fractions of cancer cells belonging to each staining intensity categories were estimated. The following formula was used to calculate the staining indices: $I = 0 \cdot f_0 + 1 \cdot f_1 + 2 \cdot f_2 + 3 \cdot f_3$, where $I$ is the staining index and $f_0$–$f_3$ are the fractions of the cells showing a defined level of staining (from 0 to 3). Theoretically, the index can vary between 0 and 3 [18].

### Table 1. The clinical characteristics of the rectal cancer patients.

|                          | Total $n = 210$ | Short-course radiotherapy, $n (%)$ | Long-course radiotherapy, $n (%)$ | Control, $n (%)$ |
|--------------------------|----------------|----------------------------------|----------------------------------|-----------------|
| **Sex**                  |                |                                  |                                  |                 |
| Male                     | 119            | 54 (45)                          | 32 (27)                          | 33 (28)         |
| Female                   | 91             | 34 (37)                          | 20 (22)                          | 37 (41)         |
| Mean age (years)         |                | 65                               | 64                               | 74              |
| **Preoperative T**       |                |                                  |                                  |                 |
| T1–2                     | 48             | 27 (56)                          | 0 (0)                            | 21 (44)         |
| T3                       | 68             | 54 (79)                          | 2 (3)                            | 12 (18)         |
| T4                       | 49             | 1 (2)                            | 45 (92)                          | 3 (6)           |
| Tx                       | 45             | 6 (13)                           | 5 (11)                           | 34 (76)         |
| **Postoperative T**      |                |                                  |                                  |                 |
| T1                       | 10             | 3 (30)                           | 2 (20)                           | 5 (50)          |
| T2                       | 65             | 32 (49)                          | 7 (11)                           | 26 (40)         |
| T3                       | 111            | 49 (44)                          | 26 (24)                          | 36 (32)         |
| T4                       | 20             | 4 (20)                           | 13 (65)                          | 3 (15)          |
| T0                       | 4              | 0 (0)                            | 4 (100)                          | 0 (0)           |
| **Postoperative N**      |                |                                  |                                  |                 |
| N0                       | 124            | 51 (41)                          | 34 (27)                          | 39 (32)         |
| N1                       | 55             | 25 (46)                          | 14 (25)                          | 16 (29)         |
| N2                       | 28             | 12 (43)                          | 4 (14)                           | 12 (43)         |
| Nx                       | 3              | 0 (0)                            | 0 (0)                            | 3 (100)         |
| **Postoperative stage**  |                |                                  |                                  |                 |
| Stage I                  | 55             | 26 (47)                          | 4 (7)                            | 25 (46)         |
| Stage II                 | 66             | 25 (38)                          | 24 (36)                          | 17 (26)         |
| Stage III                | 85             | 37 (44)                          | 20 (23)                          | 28 (33)         |
| No viable tumor left     | 4              | 0 (0)                            | 4 (100)                          | 0 (0)           |
| **Postoperative grade**  |                |                                  |                                  |                 |
| G1                       | 32             | 9 (28)                           | 10 (31)                          | 13 (41)         |
| G2                       | 134            | 56 (42)                          | 32 (24)                          | 46 (34)         |
| G3                       | 35             | 21 (60)                          | 3 (9)                            | 11 (31)         |
| Gx                       | 9              | 2 (22)                           | 7 (78)                           | 0 (0)           |
| **Circumferential margin** |               |                                  |                                  |                 |
| 0                        | 18             | 3 (17)                           | 11 (61)                          | 4 (22)          |
| 0 ≤ crm ≤ 2              | 21             | 8 (38)                           | 6 (29)                           | 7 (33)          |
| >2                       | 120            | 65 (54)                          | 25 (21)                          | 30 (25)         |
| Unknown                  | 51             | 12 (23)                          | 10 (20)                          | 29 (57)         |
| **Disease-specific outcome** |             |                                  |                                  |                 |
| Alive without recurrence | 114            | 59 (52)                          | 22 (19)                          | 33 (29)         |
| Alive with recurrence    | 9              | 3 (33)                           | 3 (33)                           | 3 (33)          |
| Died of disease          | 56             | 16 (28)                          | 20 (36)                          | 20 (36)         |
| Died of other causes     | 31             | 10 (32)                          | 7 (23)                           | 14 (45)         |

1. **T**, the extent of tumor invasion; **N**, nodal status, and stage according to the TNM classification of malignant tumors [16].

2. **Includes the T3 tumors with threatened circumferential margin involvement.**

3. **Postoperative tumor differentiation grade.**

**Evaluation of the tumor regression grade**

Tumor regression grade (TRG) after long-course RT was estimated by a pathologist (J.S.), using a scale of poor, moderate, or excellent TRG, according to a modified Dworak scale, as described previously [19]. Briefly, poor TRG was defined as minimal or no tumor regression after (chemo) RT. In case of poor response, a considerable amount of tumor cells were still remaining after treatment. In tumors with moderate response, there were only some tumor cells or tumor cell groups left in the
primary tumor (easy to find). In tumors with excellent response, very few or no tumor cells could be found.

**Statistical analysis**

Statistical analyses for rectal cancer dataset were run using IBM SPSS Statistics 22.0.0.1 for Windows (IBM Corporation, Somers, NY) software package. Frequency tables were analyzed using the c2-test, with the likelihood ratio (LR) or Fisher’s exact test for categorical variables. Contingency tables (2 × 2) were used to calculate odds ratio (OR) and 95% confidence interval (CI) using the exact method. Fisher’s exact test, Spearman’s correlation, and LR were used to assess the significance of the correlation between individual variables in univariate analysis. Interobserver reproducibility of the assessments was tested with weighted kappa, calculated using the intraclass correlation coefficient (ICC) test, in parallel mode with a two-way random model, using consistency assumption and the average-measures option to interpret the ICC (95% CI). The ICC of assessments was very good, with weighted kappa values around 0.8.

Univariate survival analysis for disease-free survival (DFS) and disease-specific survival (DSS) was based on the Kaplan–Meier method where stratum-specific outcomes were compared using log-rank (Mantel–Cox) statistics. To adjust for the covariates, a Cox proportional hazards regression model was used. Covariates (as listed separately in results) were entered in a stepwise backward manner.

The TCGA colon and rectum adenocarcinoma (COADREAD) exon expression by RNAseq (Illumina HiSeq) dataset (n = 416) was downloaded from UCSC cancer genomics browser, and analyzed by JMP Pro 11.1.1 (SAS Institute Inc., Cary, NC, USA) software. PPME1 expression distribution was studied and overall survival (OS) estimate curves were generated using Kaplan–Meier method (n = 396). Log-rank chi-square test was used to assess the significance of correlation between variables. To study the significance of PPME1 mRNA expression compared to covariate variables, Cox proportional hazards regression model was fitted for the COADREAD dataset. Model fitting was done in R version 3.1.2 [20] using package “Survival v.2.37-7” [21]. To make the results comparable, a set of covariates corresponding as closely to the clinical variables in the rectal cancer dataset as possible was aggregated from TCGA clinical data.

The statistical analyses of western blots was performed with MS excel using two-tailed Student’s paired t-test. All statistical tests were two-sided and declared significant at a P-value of <0.05.

**Results**

**Validation of the specificity of PME-1 antibody in CRC cell lines**

In order to confirm the specificity of PME-1 antibody to be used for immunohistochemistry of patient tumor material, we tested a PME-1 antibody in colon cancer cell lines, HCA-7, and CW-2. PME-1-specific siRNA was used to knockdown its expression in these cells, which were lysed and subjected to western blotting with PME-1 (clone B-12) mouse monoclonal antibody (Fig. 1A). This antibody
recognized only one band corresponding to the molecular weight of PME-1 (44 kDa) in the control (Scr. siRNA transfected) cells. The intensity of this band was greatly reduced in the cells transfected with PME-1 siRNA, suggesting that the antibody is specifically recognizing PME-1 in these cell lysates. We used the same approach to test the PME-1 antibody specificity by immunofluorescence, which corroborated the western blotting results in both HCA-7 (Fig. 1B) and CW-2 (Fig. 1C) cells. PME-1 staining was present evenly in both cytoplasm and the nucleus in CW-2 cells; however, the HCA-7 cells displayed more intense staining in the nucleus as compared to the cytoplasm (Fig. 1B).

**PME1 protein expression in rectal cancer samples**

As observed in the colon cancer cell lines, the PME-1 staining was localized both in the cytoplasm and nucleus, also in the sections made from paraffin blocks of clinical tumor samples. The staining intensity varied from one tumor to another, and the median of most intensive PME-1 index concerning both cytoplasm and nucleus was 1.2. Normal rectal epithelium was mostly negative, although in some samples there was faint background-like staining in some areas, especially in those near the cancer cells. Examples of negative, weak, moderate, and strong PME-1 expression by IHC are illustrated in Figure 2A.

**PME-1 protein expression related to clinicopathological variables**

Among men, the most intensive cytoplasmic index of PME-1 was more often below median than among women ($P = 0.027$, Pearson $\chi^2$ test). The recurrent disease was more common among patients with most intensive cytoplasmic index of PME-1 below median than those above median ($P = 0.003$, Pearson $\chi^2$ test). The correlations of these clinicopathological variables and PME-1 staining are shown in Table 2. There was no significant correlation between PME-1 most intensive cytoplasmic staining index in relation to age, the nodal status, postoperative T,
postoperative stage, postoperative grade, circumferential margin, vascular invasion, or postradiotherapy (RT) TRG (Table S1).

Table 2. Association of clinicopathological variables of rectal cancer patients with PME-1 protein expression (most intensive cytoplasmic index).

| Variable             | Total n = 195 | Below median, n (%) | Above median, n (%) | P-value² |
|----------------------|---------------|---------------------|---------------------|----------|
| Sex                  |               |                     |                     |          |
| Female               | 85            | 53 (62)             | 32 (38)             | 0.027    |
| Male                 | 110           | 85 (77)             | 25 (23)             |          |
| Recurrence           |               |                     |                     |          |
| Yes                  | 57            | 49 (86)             | 8 (14)              | 0.003    |
| No                   | 138           | 89 (64)             | 49 (36)             |          |

¹PME-1 most intensive cytoplasmic staining index could be analyzed from 195 patients only.
²Pearson chi-square test.

PME-1 expression is related to DFS of rectal cancer patients

In the univariate survival analyses for the whole cohort, tumors with the most intensive cytoplasmic index of PME-1 under median were linked to shorter DFS than those over median (110.7 vs. 116.7 months, P = 0.007, log-rank test; Fig. 2B).

The multivariate (Cox) proportional hazards regression for DFS was performed for the patients with following covariates: treatment group, sex, age (70 years as cutoff), postoperative N (positive/negative), vascular invasion (positive/negative), circumferential margin (2 mm as cutoff), and the most intensive cytoplasmic index of PME-1 (median as cutoff). The following remained as independent factors predicting a poor DFS of rectal cancer patients: sex if male (hazard ratio [HR] 4.12; 95% CI 0.25–0.98; P = 0.042), postoperative N (HR 10.33; 95% CI 1.68–8.40; P = 0.001), circumferential margin (HR 6.13; 95% CI 1.19–4.53; P = 0.013), and the most intensive cytoplasmic index of PME-1 (HR 9.28; 95% CI 1.78–14.31; P = 0.002). The multivariate (Cox)

Table 3. Multivariate survival analysis of rectal cancer patient samples and TCGA colon and rectal adenocarcinoma (COADREAD) patient samples using Cox proportional hazards regression models.

| Variables                      | Rectal cancer (n = 142)¹ | Rectal cancer (n = 114)¹ | TCGA COADREAD (n = 347)¹ |
|--------------------------------|---------------------------|---------------------------|--------------------------|
|                                | Disease-free survival     | Disease-specific survival | Overall survival         |
|                                | HR 95% CI P-value         | HR 95% CI P-value         | HR 95% CI P-value        |
| Sex                            |                           |                           |                          |
| Female                         | 1                         | 1                         | 1                        |
| Male                           | 4.12 0.25–0.98 0.042      | 1.34 0.39–1.66 0.560      | 1.68 1.01–2.79 0.046     |
| Age                            |                           |                           |                          |
| ≤70 years                      | 1                         | 1                         | 1                        |
| >70 years                      | 1.38 0.32–1.33 0.240      | 4.46 0.24–0.95 0.035      | 1.91 1.16–3.16 0.011     |
| Circumferential margin         |                           |                           |                          |
| ≤2 mm                          | 1                         | 1                         | 1                        |
| >2 mm                          | 6.13 1.19–4.53 0.013      | 1.63 0.78–3.20 0.201      |                          |
| Postoperative N²               |                           |                           |                          |
| Negative (N0)                  | 1                         | 1                         | 1                        |
| Positive (N1-2)                | 10.33 1.68–8.40 0.001     | 0.79 0.54–4.99 0.374      | 3.15 1.79–5.53 <0.001    |
| Vascular invasion³             |                           |                           |                          |
| Negative                       | 1                         | 1                         | 1                        |
| Positive                       | 1.93 0.82–3.16 0.165      | 0.42 0.36–1.66 0.519      | 1.47 0.86–2.48 0.162     |
| Disease recurrence             |                           |                           |                          |
| No                             | 21.62 15.50–840.54 <0.001 |                           |                          |
| PME-1 expression⁴,⁵            |                           |                           |                          |
| High                           | 9.28 1.78–14.31 0.002⁵    | 0.1 2.75–2.53 0.751⁴      | 2.22 1.32–3.72 0.002⁵    |
| Low                            | 1                         | 1                         | 1                        |

HR, hazard ratio; 95% CI, 95% confidence interval. Statistically significant P-values are indicated in bold.

¹Only 142 and 114 Rectal cancer patients for disease-free survival and disease-specific survival, respectively, and 347 TCGA COADREAD patients for overall survival could be analyzed for which complete data were available for all the covariates.
²Postoperative nodal status according to the TNM classification of malignant tumors [16].
³For TCGA data, vascular invasion indicates combined lymphatic, and/or venous invasion status.
⁴PME-1 most intensive cytoplasmic index (protein expression) measured by IHC (cut-off median).
⁵PME1 mRNA expression measured by RNA sequencing exon array Illumina HiSeq (cutoff −0.075).
proportional hazards regression for DSS was performed for patients with the similar covariates as that for DFS added with disease recurrence. The following remained as independent factors predicting a poor DSS: age if over 70 years (HR 4.46; 95% CI 0.24–0.95; \( P = 0.035 \)) and disease recurrence (HR 21.62; 95% CI 15.50–840.54; \( P < 0.001 \)). The multivariate (Cox) proportional hazards regression results for DFS and DSS have been presented in Table 3.

PME-1 gene expression correlates with OS of CRC patients

In an independent colon and rectum adenocarcinoma (COADREAD, \( n = 396 \)) RNA sequencing dataset (exon array IlluminaHiSeq) available from TCGA [22], we analyzed the correlation between OS and \( PPME1 \) gene expression using UCSC Cancer Genomics Browser [23, 24]. Although the \( PPME1 \) expression was normally distributed among this dataset, two distinct groups can be clearly isolated using cut-off value of −0.075 (Figure S1A). Based on this cut-off value, the data were categorized into two groups, low \( PPME1 \) (expression below −0.075) and high \( PPME1 \) (expression above −0.075) (Fig. 2C). This analysis revealed a similar trend at the mRNA expression level as was seen for PME-1 protein expression in our rectal cancer dataset. The patient group with high \( PPME1 \) gene expression (\( n = 249 \)) showed better OS (\( P = 0.005 \) log-rank \( \chi^2 \) test) than the patients with low \( PPME1 \) expression (\( n = 147 \)). Similar results were seen using median \( PPME1 \) expression (0.07014) as a cutoff (Fig. 1B and C).

The multivariate analysis of TCGA COADREAD panel was performed by Cox proportional hazards regression models to assess the effect of other possible variables contributing to the prognosis of CRC patients in the Kaplan–Meier survival analysis. This analysis was carried out in 347 patients, for which full data was available for the following covariates: sex, age (cutoff 70 years), pathologic N (positive/negative), vascular invasion (positive/negative), and \( PPME1 \) gene expression (cutoff −0.075). This analysis revealed low \( PPME1 \) expression as an independent high-risk factor (HR 2.22; 95% CI 1.32–3.72; \( P = 0.002 \)) predicting poor OS of CRC patients. Additionally, male gender (HR 1.68; 95% CI 1.01–2.79; \( P = 0.046 \)), high age (>70 years) (HR 1.91; 95% CI 1.16–3.16; 0.000

Figure 3. Modulation of survival signaling by PME-1 in colorectal cancer cells. The viability of HCA-7 and CW-2 cells transfected with Scr. or PME-1 siRNA (for 72 h) was analyzed by CellTiter-glo (CTG) (A) and WST-1 (B) assays. Bars represent fold-change values calculated over respective values for Scr. siRNA-transfected cells (\( n = 3 \)). Western blot analysis of protein lysates from siRNA-transfected HCA-7 (C) and CW-2 (D) cells, using antibodies to phosphorylated forms of AKT and ERK. The phosphoprotein expression normalized with GAPDH (loading control) is shown as fold-change values over Scr. siRNA-transfected cells (\( n = 3 \)). * \( P = 0.003 \) by Student’s paired \( t \)-test.

© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
PME-1 silencing has been shown to inhibit viability and reduce the phosphorylated AKT and ERK levels in the glioblastoma cells [9] as well as in PME-1 amplified gastric and lung cancer cells [14]. To study the alterations in survival signaling by PME-1 in colon cancer, PME-1 specific siRNA was employed to knockdown its expression and the viability was analyzed in CW-2 and HCA-7 cell lines. Neither of the cell lines displayed significant difference in viability upon PME-1 silencing, confirmed by using two different cell viability assays (Fig. 3A and B). Further immunoblotting analysis revealed that in contrast to other cancer types, PME-1 silencing did not inhibit expression of active phosphorylated forms of serine–threonine-specific protein kinases AKT-1/2/3 (p-AKT) and ERK-1/2 (p-ERK) in either of the colon cancer cell lines (Fig. 3C and D). In fact, the expression of p-AKT in HCA-7 cells was significantly higher (twofold, \( P = 0.003 \)) in PME-1 silenced cells as compared to the control (Scr. siRNA) cells (Fig. 3C); and even though the other effects did not reach the statistical significance, there was a clear trend toward higher p-AKT also in CW-2 cells and higher p-ERK in both the cell lines upon PME-1 inhibition. These findings demonstrate that opposite to other cancer types PME-1 may even decrease survival signaling in CRC cells and this may be linked to better patient outcome of rectal cancer patients with higher PME-1 expression.

Modulation of survival signaling by PME-1 in CRC cells

PME-1 expression is known to be associated with increased cell proliferation and survival signaling in human malignant gliomas and endometrical cancers [9, 13]. We studied these cellular functions in CRC cells. Since PP2A inhibition by PME-1 has been previously shown to promote phosphorylation of the AKT and ERK proteins, it is surprising that in CRC cells these prosurvival signaling events are largely unaffected or affected in an opposite manner as compared to the other types of cancer. Mechanistically, PME-1 promotes ERK pathway signaling mainly at a level upstream of Raf [9]. However, a significant proportion of the CRCs contain activating mutations in K-Ras (50%) and B-Raf (10%), which promote ERK signaling independent of the upstream stimuli [27]. In addition, the TGF-β-mediated autocrine feedback loop can further increase the Ras-Raf-ERK pathway signaling [27, 28]. These alterations may render the CRC cells insensitive to PME-1-mediated regulation. Furthermore, inactivating mutations and/or altered expression of various PP2A components [29, 30], specifically the B-subunits regulated by PME-1, might affect the activity (phosphorylation) of specific target proteins. To this end, among the PP2A B-subunits of PPP2R2B (B55) family, which are exclusively sensitive to PP2A C-subunit Leu309 methylation reversibly removed by PME-1 [31], the PPP2R2B (B55β) subunit is epigenetically silenced by DNA hypermethylation in >90% of CRCs [32]. The loss of this B-subunit promotes drug resistance in CRC by activating the survival signaling in a PI3K-AKT independent manner [32]. It may be speculated that our surprising result of a favorable outcome with high PME-1 expression is related to these altered pathways.
in CRC. Overall, the unexpected role for PME-1 in CRCs is intriguing and calls for careful examination of cancer-specific function for each of the PP2A inhibitor proteins when considering their role as biomarkers and potential targets for future cancer therapies.

**Acknowledgments**

The authors thank Otto Kauko, M.Sc., M.D. for assistance in statistical analysis of TCGA dataset. The authors also thank Foundation for the Finnish Cancer Institute, Sigrid Jusélius Foundation, and National Agency for Scientific Research, Tripoli, Libya for funding this project.

**Conflict of Interest**

None declared.

**References**

1. Naishadham, D., I. Lansdorp-Vogelaar, R. Siegel, V. Cokkinides, and A. Jemal. 2011. State disparities in colorectal cancer mortality patterns in the United States. Cancer Epidemiol. Biomarkers Prev. 20:1296–1302.

2. de Gramont, A., B. Chibaudel, A. K. Larsen, C. Tournigand, and T. Andre. 2011. The evolution of adjuvant therapy in the treatment of early-stage colon cancer. Clin. Colorectal Cancer 10:218–226.

3. van de Velde, C. J., P. G. Boelens, J. M. Borras, J. W. Coebergh, A. Cervantes, L. Blomqvist, et al. 2014. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur. J. Cancer 50:1.e–e34.

4. Janssens, V., J. Goris, and C. Van Hoof. 2005. PP2A: the expected tumor suppressor. Curr. Opin. Genet. Dev. 15:34–41.

5. Westernmark, J., and W. C. Hahn. 2008. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol. Med. 14:152–160.

6. Eichhorn, P. J., M. P. Creyghton, and R. Bernards. 2009. Protein phosphatase 2A regulatory subunits and cancer. Biochim. Biophys. Acta 1795:1–15.

7. Haesen, D., W. Sents, E. Ivanova, C. Lambrecht, and V. Janssens. 2012. Cellular inhibitors of protein phosphatase PP2A in cancer. Biomed. Res. 23:SI 197–211.

8. Junittila, M. R., P. Puustinen, M. Niemela, R. Aholu, H. Arnold, T. Bottzaauw, et al. 2007. CIP2A inhibits PP2A in human malignancies. Cell 130:51–62.

9. Puustinen, P., M. R. Junittila, S. Vanhatupa, A. A. Sablinia, M. E. Hector, K. Teittinen, et al. 2009. PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res. 69:2870–2877.

10. Khanna, A., J. E. Pimanda, and J. Westernmark. 2013. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Cancer Res. 73:6548–6553.

11. Wiegerring, A., C. Pfann, F. W. Utne, C. Otto, L. Rycka, U. Mader, et al. 2013. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PLoS One 8:e75292.

12. Oaks, J. I., R. Santhanam, C. J. Walker, S. Roof, J. G. Harb, G. Feranchak, et al. 2013. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood 122:1923–1934.

13. Wandziocz, E., M. Pusey, A. Werda, S. Bail, A. Bhaskar, M. Nestor, et al. 2014. PME-1 modulates protein phosphatase 2A activity to promote the malignant phenotype of endometrial cancer cells. Cancer Res. 74:4295–4305.

14. Li, J., S. Han, Z. Qian, X. Su, S. Fan, J. Fu, et al. 2014. Genetic amplification of PPME1 in gastric and lung cancer and its potential as a novel therapeutic target. Cancer Biol. Ther. 15:128–134.

15. Schneider, C. A., W. S. Rasband, and K. W. Eliceiri. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9:671–675.

16. Sobin, L. H., and C. Wittekind. 2002. Colon and rectum. Pp. 72–76 in L. H. Sobin and C. Wittekind, eds. TNM classification of malignant tumours, 6th ed. UICC. Wiley, New York, NY.

17. Glimelius, B., L. Pahlman, and A. Cervantes. 2010. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl 5):v82–v86.

18. Lipponen, P. K., and Y. Collan. 1992. Simple quantitation of immunohistochemical staining positivity in microscopy for histopathology routine. Acta Stereol. 11:125–132.

19. Korkeila, E., K. Talvinen, P. M. Jaakkola, H. Minn, K. Syrjanen, J. Sundstrom, et al. 2009. Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. Br. J. Cancer 100:874–880.

20. Team, R. C. 2014. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.

21. Therneau, T. M., and P. M. Grambsch. 2000. Modeling survival data: extending the Cox modeled. Springer, New York.

22. Tcgan, T. C. G. A. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330–337.

23. Zhu, J., Z. Sanborn, S. Benz, C. Szeto, F. Hsu, R. M. Kuhn, et al. 2009. The UCSC cancer genomics browser. Nat. Methods 6:239–240.
24. Cline, M. S., B. Craft, T. Swatloski, M. Goldman, S. Ma, D. Haussler, et al. 2013. Exploring TCGA pancancer data at the UCSC cancer genomics browser. Sci. Rep. 3:2652.
25. Stahlberg, A., N. Zoric, P. Aman, and M. Kubista. 2005. Quantitative real-time PCR for cancer detection: the lymphoma case. Expert Rev. Mol. Diagn. 5:221–230.
26. Marchionni, L., R. F. Wilson, S. S. Marinopoulos, A. C. Wolff, G. Parmigiani, E. B. Bass, et al. 2007. Impact of gene expression profiling tests on breast cancer outcomes. Evid. Rep. Technol. Assess. (Full Rep) 160:1–105.
27. Roberts, P. J., and C. J. Der. 2007. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291–3310.
28. Gangarosa, L. M., N. Sizemore, R. Graves-Deal, S. M. Oldham, C. J. Der, and R. J. Coffey. 1997. A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J. Biol. Chem. 272:18926–18931.
29. Tamaki, M., T. Goi, Y. Hirono, K. Katayama, and A. Yamaguchi. 2004. PPP2R1B gene alterations inhibit interaction of PP2A-Abeta and PP2A-C proteins in colorectal cancers. Oncol. Rep. 11:655–659.
30. Wang, S. S., E. D. Esplin, J. L. Li, L. Huang, A. Gazdar, J. Minna, et al. 1998. Alterations of the PPP2R1B gene in human lung and colon cancer. Science 282:284–287.
31. Janssens, V., S. Longin, and J. Goris. 2008. PP2A holoenzyme assembly: in cauda venenum (the sting in the tail). Trends Biochem. Sci. 33:113–121.
32. Tan, J., P. L. Lee, Z. Li, X. Jiang, Y. C. Lim, S. C. Hooi, et al. 2010. B55beta-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell 18:459–471.

Supporting Information

Additional supporting information may be found in the online version of this article:

Figure S1. PME-1 mRNA expression correlates with colorectal cancer patient survival.
Table S1. Clinicopathological variables and the PME-1 protein expression in rectal cancer patients.
Table S2. Multivariate survival analysis of TCGA colon and rectal adenocarcinoma (COADREAD) patients (n = 347) using Cox proportional hazards regression models.